Used in pharmaceutical research as a potent inhibitor of Janus kinase (JAK) enzymes, particularly JAK1 and JAK2. It is investigated for its potential in treating autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease due to its ability to modulate immune signaling pathways. Its structure allows for high selectivity, which may reduce off-target effects commonly seen with kinase inhibitors. Also explored in oncology for its role in disrupting cytokine-driven cancer cell proliferation, especially in myeloproliferative disorders. Shows good oral bioavailability and blood-brain barrier penetration in preclinical models, making it a candidate for central nervous system-related inflammatory conditions.